Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 458

Sort by

Sort Order Select

Journal Articles

Rivaroxaban Reduces the Levels of Extracellular Vesicles in Patients with Venous Thromboembolism and Non-Valvular Atrial Fibrillation

Sarah Kelliher, MBBS, Luisa Weiss, MSc, Paulina Szklanna, PhD, Karl Egan, PhD, Tadhg Prendiville, MB BCh BAO, Eric Moran, MB BCh BAO, Georgi Petrov, MB BCh BAO, Alfonso Blanco, PhD, Aine Lennon, MSc, Sean Murphy, MD, John Keaney, MD, Fionnuala Ni Ainle, PhD, Patricia Maguire, PhD

Blood (2019) 134 (Supplement_1): 2437.

https://doi.org/10.1182/blood-2019-126166

Published: 2019

Journal Articles

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

Caitlin R. Rausch, PharmD, Courtney D. DiNardo, MDMSc, Abhishek Maiti, MBBS, Nadya Jammal, PharmD, Tapan M. Kadia, MD, Kayleigh Marx, PharmD, Gautam M. Borthakur, MD, J Michael Savoy, PharmD, Naveen Pemmaraju, MD, Adam Dipippo, PharmD, Naval G. Daver, MD, Serena Chew, PharmD, Koji Sasaki, MD, Ghayas C. Issa, MD, Kiran Naqvi, MDMPH, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2640.

https://doi.org/10.1182/blood-2019-131988

Published: 2019

Journal Articles

Pediatric Preclinical Testing Consortium Evaluation of the Novel Anti-Microtubule Drug E7130 in Xenograft Models of Early T-Cell Precursor Acute Lymphoblastic Leukemia

Richard B. Lock, PhD, Kathryn Evans, Connor D Jones, Narimanne El-Zein, Katerina Bendak, PhD, Cara E Toscan, PhD, Chelsea Mayoh, Stephen W Erickson, PhD, Beverly A Teicher, PhD, Malcolm A Smith, MD PhD

Blood (2019) 134 (Supplement_1): 3875.

https://doi.org/10.1182/blood-2019-123867

Published: 2019

Journal Articles

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Martine Humbert, PhD, Armelle Goubard, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 2075.

https://doi.org/10.1182/blood-2019-122540

Published: 2019

Journal Articles

Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin

Mohammed Gbadamosi, BS, Abdelrahman H. Elsayed, MSc, Rhonda E. Ries, MA, Soheil Meshinchi, MD PhD, Jatinder K Lamba, M.Sc., PhD

Blood (2019) 134 (Supplement_1): 1401.

https://doi.org/10.1182/blood-2019-131210

Published: 2019

Journal Articles

Evaluation of Clinical, Hematological and Flow Cytometry Dates in Elderly Patients with Acute Myeloid Leukemia: Impact on Clinical Outcome

Alessandra Suelen Jardim Silva, Lenilton Silva DA Silva Júnior, Jr., MSc, Gustavo Henrique de Medeiros Oliveira, PhD, Antonia Eduarda Martins Oliveira Elói Silva, João Pedro Andrade Lima, Victor lima Soares, Rodrigo Villar Freitas, MD, Frank Bahia, MD, Taissa Moura Oliveira, MSc, Dany GKC Silva, Valéria SF Sales, PhD, Hugo Diogenes De Oliveira Paiva, MD, Rafael Santiago Araujo, Aldair Sousa Paiva, PhDMD, Geraldo Barroso Cavalcanti, Jr., PhD

Blood (2019) 134 (Supplement_1): 5115.

https://doi.org/10.1182/blood-2019-127319

Published: 2019

Journal Articles

In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia

Armelle Goubard, PhD, Martine Humbert, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 5142.

https://doi.org/10.1182/blood-2019-127143

Published: 2019

Journal Articles

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Kidist Ashami, BA, Sena Kim, PhD, Ravi Vij, MBBS, Julie K. Ritchey, Srikanth Santhanam, PhD, Sora Lim, MS, Sarah Peterson, Matthew Ciorba, MD, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2019) 134 (Supplement_1): 4420.

https://doi.org/10.1182/blood-2019-126167

Published: 2019

Journal Articles

Targeting Nucleolin for Reversal of Chemotherapy Resistance in Acute Lymphoblastic Leukemia

Jianda Hu, PhD, Yanxin Chen, MD PhD, Zhengjun Wu, Lingyan Wang, PhDMD, Jingjing Wen, Peifang Jiang, Yun Zhang, Minhui Lin, MD PhD

Blood (2019) 134 (Supplement_1): 5058.

https://doi.org/10.1182/blood-2019-127073

Published: 2019

Journal Articles

Increased Risk of Early Hematologic Toxicity during Maintenance Therapy in Acute Lymphoblastic Leukemia Patients of South Indian Origin Carrying NUDT15*3 Allele

Sunitha Kodidela, PhD, Dorababu Patchva, PhD, Dimpal Thakkar:, PhD, Biswajit Dubashi, DM, Rajan Sundaram, M.Sc, Ravi Prasad Nidanapu, PhD, Muralidharan Nivedita, PhD, Anil Aribandi, MD MRCP, FRCPath, Suresh Chandra Pradhan, MD, Chakradhara RS Uppugunduri, PhD

Blood (2019) 134 (Supplement_1): 5059.

https://doi.org/10.1182/blood-2019-129967

Published: 2019

Journal Articles

AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes

Armelle Goubard, PhD, Martine Humbert, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 5154.

https://doi.org/10.1182/blood-2019-127021

Published: 2019

Journal Articles

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Trisha Kissoon, MD MBA

Blood (2019) 134 (Supplement_1): 5062.

https://doi.org/10.1182/blood-2019-129511

Published: 2019

Journal Articles

Melatonin Increases the Chemosensitivity of Diffuse Large B Cell Lymphoma Cells to Epirubicin By Inhibiting P-Glycoprotein Expression Via the NF-Κb Pathway

Xiuhua Sun, MD, Hong Qin, MD PhD

Blood (2019) 134 (Supplement_1): 5064.

https://doi.org/10.1182/blood-2019-128271

Published: 2019

Journal Articles

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 113.

https://doi.org/10.1182/blood-2019-123047

Published: 2019

Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Blood (2019) 134 (Supplement_1): 130.

https://doi.org/10.1182/blood-2019-126787

Published: 2019

Journal Articles

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction

Rafee Talukder, MD, Martha P. Mims, MD PhD, Gustavo A. Rivero, MD

Blood (2019) 134 (Supplement_1): 1438.

https://doi.org/10.1182/blood-2019-131581

Published: 2019

Journal Articles

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Blood (2018) 132 (Supplement 1): 5440.

https://doi.org/10.1182/blood-2018-99-118600

Published: 2018

Journal Articles

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Akiko Mita, MD, Maiko Abumiya, PhD, Saori Takahashi, Ms, Yoshihiro Kameoka, MD PhD, Masatomo Miura, PhD, Naoto Takahashi, MD

Blood (2018) 132 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2018-99-111905

Published: 2018

Journal Articles

CRISPR Activation Screen for HDAC Inhibitor Resistance

Huihui Tang, PhD, Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD PhD, Olga Dashevsky, PhD, Brian Glassner, PhD, Sondra L. Downey-Kopyscinski, PhD, Sara Gandolfi, MD, Michal Sheffer, PhD, Megan Bariteau, BSc, John G Doench, PhD, Constantine S. Mitsiades, MD PhD

Blood (2018) 132 (Supplement 1): 3958.

https://doi.org/10.1182/blood-2018-99-119044

Published: 2018

Journal Articles

Diffuse Alveolar Hemorrhage Secondary to Direct Oral Anticoagulants: A Systematic Review of Reported Cases

Fawzi Abu Rous, MD, Abdullah al-Abcha, Layan El-khatib, Shiva Shrotriya, MD MPH, Prajwal Dhakal, MBBS

Blood (2018) 132 (Supplement 1): 5069.

https://doi.org/10.1182/blood-2018-99-115545

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rivaroxaban Reduces the Levels of Extracellular Vesicles in Patients with Venous Thromboembolism and Non-Valvular Atrial Fibrillation

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

Pediatric Preclinical Testing Consortium Evaluation of the Novel Anti-Microtubule Drug E7130 in Xenograft Models of Early T-Cell Precursor Acute Lymphoblastic Leukemia

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin

Evaluation of Clinical, Hematological and Flow Cytometry Dates in Elderly Patients with Acute Myeloid Leukemia: Impact on Clinical Outcome

In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Targeting Nucleolin for Reversal of Chemotherapy Resistance in Acute Lymphoblastic Leukemia

Increased Risk of Early Hematologic Toxicity during Maintenance Therapy in Acute Lymphoblastic Leukemia Patients of South Indian Origin Carrying NUDT15*3 Allele

AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Melatonin Increases the Chemosensitivity of Diffuse Large B Cell Lymphoma Cells to Epirubicin By Inhibiting P-Glycoprotein Expression Via the NF-Κb Pathway

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

CRISPR Activation Screen for HDAC Inhibitor Resistance

Diffuse Alveolar Hemorrhage Secondary to Direct Oral Anticoagulants: A Systematic Review of Reported Cases

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only